Soft tissue sarcoma presenting with metastatic disease

Cancer

Volumn 117, Issue 2, 2011, Pages 372-379

  Ferguson, Peter C ^a,b,c   Deheshi, Benjamin M ^a,b,c   Chung, Peter ^b   Catton, Charles N ^b   O'Sullivan, Brian ^b   Gupta, Abha ^b   Griffin, Anthony M ^a   Wunder, Jay S ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

chemotherapy; lymph nodes; metastases; palliative; radiotherapy; sarcoma; surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ALVEOLAR SOFT PART SARCOMA; AMPUTATION; ANGIOSARCOMA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHONDROSARCOMA; CLEAR CELL SARCOMA; CONTROLLED STUDY; EPITHELIOID SARCOMA; EWING SARCOMA; FEMALE; FIBROSARCOMA; HUMAN; LEIOMYOSARCOMA; LIMB SALVAGE; LIPOSARCOMA; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; NERVE SHEATH TUMOR; OSTEOSARCOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SURVIVAL RATE; SYNOVIAL SARCOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; SARCOMA; TREATMENT OUTCOME;

EID: 78650973875     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25418     Document Type: Article

References (26)

1. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
2. Ramanathan RC, A'Hern R, Fisher C, Thomas JM,. Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol. 1999; 6: 57-69.
3. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
4. Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM, Brennan MF,. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 1999; 85: 389-395.
5. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999; 229: 602-610; discussion 610-602.
6. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS,. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2003; 57: 739-747.
7. Casson AG, Putnam JB, Natarajan G, et al. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer. 1992; 69: 662-668.
8. Riad S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res. 2004; 426: 129-134.
9. Fong Y, Coit DG, Woodruff JM, Brennan MF,. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993; 217: 72-77.
10. Mazeron JJ, Suit HD,. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987; 60: 1800-1808.
11. Bramwell VH, Anderson D, Charette ML,. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev. 2003; 3: CD003293.
12. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993; 11: 1269-1275.
13. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13: 1537-1545.
14. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000; 18: 2676-2684.
15. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of 2 investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol. 2007; 25: 3144-3150. (Pubitemid 47218064)
16. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I,. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008; 112: 1585-1591.
17. Portera CA Jr, Ho V, Patel SR, et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer. 2001; 91: 585-591.
18. Davis AM, O'Sullivan B, Bell RS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2002; 20: 4472-4477.
19. Schwartz DL, Einck J, Bellon J, Laramore GE,. Fast neutron radiotherapy for soft tissue and cartilaginous sarcomas at high risk for local recurrence. Int J Radiat Oncol Biol Phys. 2001; 50: 449-456.
20. McCahill L, Ferrell B,. Palliative surgery for cancer pain. West J Med. 2002; 176: 107-110.
21. Miner TJ, Brennan MF, Jaques DP,. A prospective, symptom related, outcomes analysis of 1022 palliative procedures for advanced cancer. Ann Surg. 2004; 240: 719-726; discussion 726-717.
22. Miner TJ, Jaques DP, Tavaf-Motamen H, Shriver CD,. Decision making on surgical palliation based on patient outcome data. Am J Surg. 1999; 177: 150-154.
23. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-579.
24. Schipper H, Clinch J, McMurray A, Levitt M,. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984; 2: 472-483.
25. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K,. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991; 7: 6-9.
26. Malawer MM, Buch RG, Thompson WE, Sugarbaker PH,. Major amputations done with palliative intent in the treatment of local bony complications associated with advanced cancer. J Surg Oncol. 1991; 47: 121-130.